Differences in Treatment Outcomes Between Patients With MS Receiving Ocrelizumab and Those Receiving Ofatumumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
Ann. Neurol 2024 Nov 25;[EPub Ahead of Print], SG Meuth, S Wolff, A Mück, A Willison, K Kleinschnitz, S Räuber, M Pawlitzki, FF Konen, T Skripuletz, M Grothe, T Ruck, HB Huttner, C Kleinschnitz, T Bopp, R Pul, BAC Cree, HP Hartung, K Möllenhoff, S PfeufferFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.